CL Item

Anal Hpv Dna Pcr Result: Type 16; Positive, Negative Type 18; Positive, Negative (Anal HPV DNA PCR result: Type 16; positive, negative Type 18; positive, negative)

CL Item

Did The Participant Have A Normal Anal Cytological Results, Or Ascus/lsil Result, Within 45 Days Prior To Entry (Did the participant have a normal anal cytological results, or ASCUS/LSIL result, within 45 days prior to entry)

CL Item

Is The Participant Receiving Antiretroviral Therapy (Is the participant receiving antiretroviral therapy)

CL Item

Karnofsky Performance Status (must Be >=70 And Assessed Within 45 Or Fewer Days Prior To Entry) (Karnofsky performance status (must be >=70 and assessed within 45 or fewer days prior to entry))

CL Item

Were The Following Hematologic Parameters Met And Performed Within 45 Days Prior To Study Entry: Absolute Neutrophil Count (>750 Cells/mm^3); Hemoglobin (>=9.0 G/dl); Platelet Count (>=100,000/ Mm^3) (Were the following hematologic parameters met and performed within 45 days prior to study entry: Absolute neutrophil count (>750 cells/mm^3); Hemoglobin (>=9.0 g/dL); Platelet count (>=100,000/ mm^3))

CL Item

Were The Following Laboratory Parameters Met And Performed Within 45 Days Prior To Study Entry: Creatinine (<=3 X Uln); Ast (<=3 X Uln); Alt (<=3 X Uln); Bilirubin (total Or Direct) (<=2.5 X Uln) (Were the following laboratory parameters met and performed within 45 days prior to study entry: Creatinine (<=3 x ULN); AST (<=3 x ULN); ALT (<=3 x ULN); Bilirubin (total or direct) (<=2.5 x ULN))

CL Item

Is The Participant's Screening Cd4+ Cell Count >200 Cells/mm^3 (Is the participant's screening CD4+ cell count >200 cells/mm^3)

CL Item

Is The Participant's Screening Plasma Hiv-1 Rna Result (i.e. Viral Load) Below The Limit Of Detection (with The Lower Limit Of Detection 200 Copies Or Less) Or Detectable But < 200 Copies/ml (Is the participant's screening plasma HIV-1 RNA result (i.e. viral load) below the limit of detection (with the lower limit of detection 200 copies or less) or detectable but < 200 copies/ml)

CL Item

Has The Participant Received Antiretroviral Therapy Continuously (i.e. No Interruptions Of Antiretroviral Therapy Lasting Longer Then 7 Days) For At Least 6 Months Prior To Entry (Has the participant received antiretroviral therapy continuously (i.e. no interruptions of antiretroviral therapy lasting longer then 7 days) for at least 6 months prior to entry)

CL Item

Has The Participant's Antiretroviral Therapy Remained Unchanged In The 30 Days Prior To Entry (Has the participant's antiretroviral therapy remained unchanged in the 30 days prior to entry)

CL Item

Is The Participant's Screening Cd4+ Cell Count >=350 Cells/mm^3 (within 90 Days Prior To Entry) (Is the participant's screening CD4+ cell count >=350 cells/mm^3 (within 90 days prior to entry))

CL Item

Is The Participant Planning To Remain Off Antiretroviral Therapy Within 28 Weeks After Entry (Is the participant planning to remain off antiretroviral therapy within 28 weeks after entry)

CL Item

Did The Participant Have Serious Illness Requiring Systemic Treatment And/or Hospitalization Within 45 Days Prior To Entry (Did the participant have serious illness requiring systemic treatment and/or hospitalization within 45 days prior to entry)

CL Item

Does The Participant Have A History Of Anal Cytological Result With Hsil, Atypical Squamous Cells Suggestive Of Hsil, Or Suggestive Of Carcinoma (Does the participant have a history of anal cytological result with HSIL, atypical squamous cells suggestive of HSIL, or suggestive of carcinoma)

CL Item

Does The Participant Have A History Of Anal Or Perianal Carcinoma (Does the participant have a history of anal or perianal carcinoma)

CL Item

Does The Participant Have A History Of High Grade Ain (i.e. Ain 2 Or 3) Or High Grade Perianal Intraepithelial Neoplasia (Does the participant have a history of high grade AIN (i.e. AIN 2 or 3) or high grade perianal intraepithelial neoplasia)

CL Item

Does The Participant Have Active Drug Or Alcohol Use Or Dependence That, In The Opinion Of The Site Investigator, Would Interfere With Adherence To Study Requirements (Does the participant have active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements)

CL Item

Has The Participant Received Any Systemic Antineoplastic Or Immunomodulatory Treatment, Systemic Corticosteroids, Investigational Vaccines, Interleukins, Interferons, Growth Factors, Or Ivig, <=45 Days Prior To Entry (Has the participant received any systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids, investigational vaccines, interleukins, interferons, growth factors, or IVIG, <=45 days prior to entry)

CL Item

Is The Participant Receiving Anticoagulation Therapy Other Than Acetylsalicylic Acid At The Time Of Entry (Is the participant receiving anticoagulation therapy other than acetylsalicylic acid at the time of entry)